Results 61 to 70 of about 4,266 (228)

Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case–control study

Osteoporosis International
This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis.
Toshitaka Yukishima, Kosuke Ebina, Y. Etani, T. Noguchi, Shin-ichiro Ohmura, Ken Nakata, S. Okada, T. Kobayakawa   +7 more
semanticscholar   +1 more source

Romosozumab : un nouveau traitement de l'ostéoporose sévère

, 2021
Le romosozumab est un anticorps monoclonal dirigé contre la sclérostine, dont le double effet osseux est de stimuler la formation et diminuer la résorption.
Ferrari, Serge Livio, Uebelhart, Brigitte Florence   +1 more
core  

Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study.

Journal of Clinical Endocrinology and Metabolism
CONTEXT Romosozumab, a monoclonal sclerostin antibody, is a recently approved highly potent anti-osteoporotic agent with osteoanabolic properties. Clinical use of Romosozumab is hindered by the fear of adverse cardiovascular (CV) events raised following ...
J. Stokar, A. Szalat
semanticscholar   +1 more source

Romosozumab Use and Cardiovascular Events

Journal of Bone and Mineral Research, 2022
*
Fusaro Maria, Tripepi Giovanni
openaire   +2 more sources

A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.

, 2018
Context Globally, one in five men aged >50 years is predicted to experience an osteoporotic fracture. Because of the treatment gap in osteoporosis and the paucity of bone-forming agents for men, new osteoporosis treatments are needed.
Goemaere, Stefan, Tomasz Blicharski, Miller, Paul D, Chen, Li, Lippuner, Kurt, E Michael Lewiecki, Kurt Lippuner, Stephane Horlait, Miyauchi, Akimitsu, Judy Maddox, Blicharski, Tomasz, Stefan Goemaere, Akimitsu Miyauchi, Meisner, Paul D, Li Chen, Lewiecki, E Michael, Maddox, Judy, Paul D Miller, Paul D Meisner, Horlait, Stephane   +19 more
core   +1 more source

Targeting Endogenous Lipophagy: A Novel Strategy to Enhance MSC Osteogenesis and Mineralization for Senile Osteoporosis Therapy

Advanced Science, EarlyView.
Schematic representation of the role of lipophagy in bone mesenchymal stem cells(MSCs). In healthy MSCs, functional lipophagy efficiently degrades lipid droplets to support oxidative phosphorylation and cellular energy production, thereby facilitating osteogenic differentiation and matrix mineralization.
Chaoqiang Chen, Zhidong Liu, Yanhang Sun, Xiaojun Xu, Zhexiao Lan, Junhao Zhao, Peitao Xu, Guiwen Ye, Jinteng Li   +8 more
wiley   +1 more source

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study

JBMR Plus, 2019
Radiographic vertebral fractures (VFxs) are the most common fractures in osteoporosis and are associated with increased morbidity, mortality, and costs. A subset of VFxs manifest clinically, usually with a sudden onset of severe back pain. Romosozumab is
Piet Geusens, Mary Oates, Akimitsu Miyauchi, Jonathan D Adachi, Marise Lazaretti‐Castro, Peter R Ebeling, Carlos Augusto Perez Niño, Cassandra E Milmont, Andreas Grauer, Cesar Libanati   +9 more
doaj   +1 more source

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

, 2021
Summary: Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic analysis indicates that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis ...
Lorentzon, M., Borgstrom, F, Ström, O.,, Willems, D., Söreskog, E.,, Willems, D.,, Akesson, KE, Soreskog, E, Lorentzon, M, Borgström, F.,, Berling, P, Lorentzon, M.,, Ström, O., Lindberg, I., Willems, D, Lorentzon, Mattias,, Åkesson, K. E., Strom, O, Kanis, JA, Åkesson, K. E.,, Lindberg, I.,, Kanis, J. A.,, Berling, P.,, Borgström, F., Lindberg, I, Kanis, J. A., Berling, P., Lund University., Söreskog, E.   +28 more
core   +1 more source

Romosozumab (Evenity)

Canadian Journal of Health Technologies, 2021
CADTH recommends that Evenity should be reimbursed by public drug plans for the treatment of osteoporosis in postmenopausal women if certain conditions are met. Evenity should only be covered to treat postmenopausal women with a history of osteoporosis-related fracture and who are likely to have such a fracture in the future and who have never ...
openaire   +3 more sources

Mind the gap: Adherence to denosumab dosing and cessation guidelines in Australian residential aged care

British Journal of Clinical Pharmacology, EarlyView.
This original research used medication administration data to explore adherence to treatment guidelines for the most common osteoporosis medications in long‐term residential aged care (RAC) in Australia. The paper highlights gaps in adherence to treatment guidelines that must be addressed to improve outcomes of older adults living in RAC.
Marea O'Donnell, Johanna I. Westbrook, Bayzidur Rahman, Isabelle Meulenbroeks, Nasir Wabe, Ian D. Cameron, Mark Morgan, Magdalena Z. Raban   +7 more
wiley   +1 more source